Psychedelics: New Horizons for the Treatment of Psychiatric Disorders that Deteriorate Global Human Health

Session Description

This session will introduce to the ASCPT membership the promising potential of psychedelics to treat the wide range of disorders noted. Psychedelics presently being investigated include MDMA, DMT, psilocybin and LSD. The clinical development of these agents presents unique challenges due in large part to challenges masking their psychedelic effects in gold-standard randomized, blinded, placebo-controlled trials.

Learning Objectives

1. Upon completion, participants will be familiar with the basic pharmacology of psychedelics.
2. Upon completion, participants will derive an appreciation of the clinical pharmacology of psychedelics, including the complex relationship between the psychedelic experience and therapeutic effect.
3. Upon completion, participants will be aware of the regulatory principles that guide approval and scheduling of psychedelics.

Session Schedule

1:30 PM - 1:35 PM MT
Introduction
Robert E. Stratford, Jr., PhD and Gina Pastino, PhD

1:35 PM - 1:55 PM MT
Overview of Psychedelics Pharmacology
John McCorvy, PhD

1:55 PM - 2:15 PM MT
Clinical Pharmacology and Clinical Development of Psychedelics
Matthew W. Johnson, PhD

2:15 PM - 2:30 PM MT
Q&A and Closing Remarks